The Pulse
Vera Health Raises $28.5 Million for Clinical AI Search
Vera Health announced a $28.5 million Series A led by Threshold Ventures, bringing its total funding to $32 million. The company says more than 800,000 clinicians in 190 countries use its AI search platform, which links answers to medical e
AI.info Team · Written with AI · fact-checked ·
Vera Health announced a $28.5 million Series A on October 27, saying more than 800,000 clinicians now use its medical search platform. Threshold Ventures led the round, joined by Mantis VC and SV Angel; existing investors Y Combinator and Gradient also increased their backing. The company said the financing brings its total funding to $32 million.
Vera says clinicians in 190 countries use the service, which is free for licensed clinicians and medical trainees. The company describes most of its growth as coming through recommendations among colleagues, rather than a large sales operation. It plans to spend the new capital on its clinical evidence infrastructure, expansion into additional healthcare markets and partnerships with medical societies, publishers and health systems.
Search first, answer second
Vera’s stated approach is to retrieve medical evidence before generating a response. The company says its system searches more than 60 million peer-reviewed publications, clinical guidelines, consensus statements and drug labels. It evaluates sources using factors such as study design, level of evidence, cohort size, recency, journal quality and citation impact.
Answers link claims to supporting research, and Vera color-codes them to signal the strength of the available evidence. In its announcement, the company says the system can surface research on rare conditions even when the available evidence is limited to a small case series or a report about one patient. The aim, it says, is to make those limits visible rather than present uncertain findings as settled.
“Unlike other tools, we believe there’s value in making uncertainty visible,” said Maxime Allouch, Vera’s co-founder. He added that the evidence grade shapes what the system retrieves and writes, while the clinician supplies the patient context and judgment. The description comes from the company; the announcement does not provide an independent evaluation of the platform’s performance in routine care.
Local guidance for a global user base
Vera argues that clinical decisions depend on local practice as well as international research. A physician may need guidance that reflects national recommendations, specialty needs or a hospital’s own protocols. The company says its platform prioritizes locally relevant guidance while drawing on research from around the world.
Its Vera Spaces product lets health systems add internal clinical protocols and pathways alongside national guidelines and medical literature. Vera also points to a partnership with the American College of Emergency Physicians, which brings the organization’s clinical policies into the search platform with source attribution. That partnership is one example of the institutional relationships the company says it wants to deepen with the new funding.
“Medicine is global, yet most tools in our space were built for a single geography,” Allouch said. Vera reports that about one in four physicians in Spain and Italy, and one in seven in France, use the platform. Those adoption figures are company-provided estimates, not independently audited user counts.
Growth claims meet a crowded clinical search market
Vera says its user base grew from a few thousand clinicians a year ago to more than 800,000, while daily questions rose from a few thousand to hundreds of thousands. It also says the team has 12 employees. The company’s announcement does not disclose the round’s valuation or provide a breakdown of revenue, so the funding amount alone does not show how the business will convert its reported reach into a durable commercial model.
The company says it will keep individual access free for licensed clinicians and medical trainees worldwide as it expands its products for healthcare institutions. Its central product claim is that medical search should expose the evidence and its limits, not just return a fluent answer. The new capital is earmarked for the infrastructure, market expansion and partnerships needed to extend that model.